The Big Ten Conference officially announced a partnership with Biodesix, Inc., and Quidel Corporation Tuesday, as the league works to reach its rigorous COVID-19 testing standards.
Biodesix, a leading diagnostic company with a focus on lung disease, will oversee and manage on site antigen testing sanctioned by Quidel, the manufacturer of the FDA-authorized SOFIA 2 SARS rapid antigen test, per release. Individuals who are presumptively positive according to results of this antigen surveillance testing will be referred to their own institution’s health staff for confirmatory PCR testing.
“Along with its medical and scientific capabilities as a certified laboratory, Biodesix is committed to helping the Big Ten meet [its] testing requirements and reporting protocols,” said Dr.